Automated insulin delivery among adults with type 1 diabetes for up to 2 years: a real-world, multicentre study.

Laura E DonaldsonSpiros FourlanosSara VogrinRichard J MacIsaacPeter G ColmanSybil A McAuley

Published in: Internal medicine journal (2023)

Early glucose improvements were observed after real-world automated insulin delivery initiation, sustained up to 2 years, without excess adverse events. Greatest benefits were observed among individuals with highest glycaemia pre-initiation. Future-generation systems with increased user-friendliness may enhance therapy continuation. This article is protected by copyright. All rights reserved.

Keyphrases

type diabetes
machine learning
deep learning
high throughput
glycemic control
blood pressure
stem cells
mesenchymal stem cells
bone marrow
single cell
replacement therapy